Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine

Gemcitabine‐based therapy remains the mainstay of treatment for patients with biliary tract cancers (BTCs) with no second‐line treatment(s) established yet. Aberrant activation of the MAPK pathway in patients with BTC indicates its importance in BTC. Trametinib is a potent, highly selective, alloste...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Sci
Päätekijät: Ikeda, Masafumi, Ioka, Tatsuya, Fukutomi, Akira, Morizane, Chigusa, Kasuga, Akiyoshi, Takahashi, Hideaki, Todaka, Akiko, Okusaka, Takuji, Creasy, Caretha L., Gorman, Shelby, Felitsky, Daniel J., Kobayashi, Mikiro, Zhang, Fanghong, Furuse, Junji
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2017
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765304/
https://ncbi.nlm.nih.gov/pubmed/29121415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13438
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia